Research & Development

Committed to Innovation

Since founding Servier in 1954, Dr Jacques Servier has grown Servier to become a leading pharmaceutical group with an established global presence in 140 countries. Employing more than 20,000 personnel worldwide, 15% of Servier staff work in research and development (R&D).

Our committment to, and focus on, R&D has led to a prolific output of more than 50,000 compounds. Importantly this research has contributed to improving health outcomes for some of the world's most urgent medical needs including treatments for coronary heart disease, heart failure, hypertension, diabetes, osteoporosis and depression.

As a privately owned company, Servier's independence from shareholder interests provides the ability to focus on new first-in-class chemical entities to help address many of the world's unmet urgent medical needs

It takes on average 12 years and 1.4 billion dollars to bring a medicine to market

DISCOVERY TESTING CLINICAL TRIALS REGISTRATION PBS LISTING MARKETING MONITORING
Extraction or synthesis of new chemical or biological substance Pre-Clinical Laboratory and animal testing

PHASE I

20–80 healthy volunteers used to determine safety, pharmacological activity & dosage

PHASE II

100–300 patient volunteers used to determine efficacy and safety

PHASE III

1,000–5,000 patient volunteers used to determine clinical benefit and incidence of adverse reactions

35,000–100,000 pages of data submitted for evaluation by the Therapeutic Goods Administration

Determination of cost eff ectiveness

Products promoted to medical profession Post-market monitoring safety and efficacy when used in wider population
2-10 YEARS 4 YEARS 7 YEARS 1.5-2 YEARS 8 MONTHS (MIN) ONGOING ONGOING